相似文献
1
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. doi: 10.1073/pnas.0606176103. Epub 2006 Sep 22.
2
Imatinib spells BAD news for Bcr/abl-positive leukemias.
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14651-2. doi: 10.1073/pnas.0607135103. Epub 2006 Sep 26.
3
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Cancer Res. 2005 Oct 15;65(20):9436-44. doi: 10.1158/0008-5472.CAN-05-0972.
4
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Cell Death Differ. 2007 Sep;14(9):1667-77. doi: 10.1038/sj.cdd.4402168. Epub 2007 May 18.
5
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Exp Hematol. 2012 May;40(5):367-78.e2. doi: 10.1016/j.exphem.2012.01.004. Epub 2012 Jan 10.
6
The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
Oncotarget. 2016 Jan 19;7(3):2721-33. doi: 10.18632/oncotarget.5436.
7
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.
8
Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.
Cancer Biol Ther. 2007 Jun;6(6):912-9. doi: 10.4161/cbt.6.6.4101. Epub 2007 Mar 5.
9
CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
Exp Hematol. 2012 Sep;40(9):724-737.e2. doi: 10.1016/j.exphem.2012.05.007. Epub 2012 May 24.
10
FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Apoptosis. 2013 Nov;18(11):1437-1446. doi: 10.1007/s10495-013-0882-y.
引用本文的文献
1
Comprehensive landscape of cell death mechanisms: from molecular cross-talk to therapeutic innovation in oncology.
Front Cell Dev Biol. 2025 Jul 16;13:1611055. doi: 10.3389/fcell.2025.1611055. eCollection 2025.
2
Therapy-induced senescence is a transient drug resistance mechanism in breast cancer.
Mol Cancer. 2025 May 1;24(1):128. doi: 10.1186/s12943-025-02310-0.
3
Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities.
Leukemia. 2025 Jan;39(1):211-221. doi: 10.1038/s41375-024-02439-9. Epub 2024 Oct 22.
4
A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling.
Cancer Med. 2020 Sep;9(18):6739-6751. doi: 10.1002/cam4.3231. Epub 2020 Jul 28.
5
The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment.
Front Pharmacol. 2024 Apr 16;15:1376955. doi: 10.3389/fphar.2024.1376955. eCollection 2024.
6
Targeting eIF5A2 reduces invasion and reverses chemoresistance in SCC-9 cells .
Histol Histopathol. 2024 Apr;39(4):463-470. doi: 10.14670/HH-18-637. Epub 2023 Jun 6.
7
BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond.
Hemasphere. 2023 Jun 8;7(6):e912. doi: 10.1097/HS9.0000000000000912. eCollection 2023 Jun.
8
Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer.
Genes (Basel). 2022 Nov 22;13(12):2183. doi: 10.3390/genes13122183.
9
BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.
Cell Death Discov. 2022 Nov 15;8(1):457. doi: 10.1038/s41420-022-01211-1.
10
BCL-2 protein family: attractive targets for cancer therapy.
Apoptosis. 2023 Feb;28(1-2):20-38. doi: 10.1007/s10495-022-01780-7. Epub 2022 Nov 7.
本文引用的文献
1
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Nature. 2005 Jun 2;435(7042):677-81. doi: 10.1038/nature03579. Epub 2005 May 15.
2
Polycystic kidney disease prevented by transgenic RNA interference.
Cell Death Differ. 2005 Jul;12(7):831-3. doi: 10.1038/sj.cdd.4401603.
3
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
Mol Cell. 2005 Feb 4;17(3):393-403. doi: 10.1016/j.molcel.2004.12.030.
4
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.
Oncogene. 2005 Mar 31;24(14):2317-29. doi: 10.1038/sj.onc.1208421.
5
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood. 2005 Apr 1;105(7):2640-53. doi: 10.1182/blood-2004-08-3097. Epub 2004 Dec 23.
6
The pathophysiology of mitochondrial cell death.
Science. 2004 Jul 30;305(5684):626-9. doi: 10.1126/science.1099320.
7
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.
Mol Cell Biol. 2004 Jul;24(14):6172-83. doi: 10.1128/MCB.24.14.6172-6183.2004.
8
Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim.
EMBO J. 2003 Dec 15;22(24):6653-64. doi: 10.1093/emboj/cdg635.
9
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.
Cancer Cell. 2003 Oct;4(4):321-8. doi: 10.1016/s1535-6108(03)00244-7.
10
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.
Oncogene. 2003 Oct 2;22(43):6785-93. doi: 10.1038/sj.onc.1206792.
Zotero 插件